恩替卡韦与拉米夫定在术前HBV低复制患者肝移植术后抗病毒疗效及经济学对比

发布时间：2018-02-10 18:40

本文关键词： 乙肝肝移植恩替卡韦拉米夫定 HBV再感染血清学转阴　出处：《实用医学杂志》2015年12期 　论文类型：期刊论文

【摘要】：目的:对比恩替卡韦与拉米夫定在预防术前HBV低复制患者肝移植术后乙肝复发的疗效及经济学对比,探讨肝移植术后预防HBV再感染的治疗策略。方法:选取自2006年7月至2013年7月于我院行肝移植的患者进行前瞻性研究,通过分析术后随访血清学转阴及HBV再感染情况进行统计分析。结果:恩替卡韦组51例,术后1个月累积转阴率98.04%,发现3例出现再感染,再感染率5.88%,平均转阴时间9.73 d。拉米夫定组26例,术后1个月累积转阴率100%,有3例出现了HBV再感染,再感染率为11.54%,平均转阴时间为5.11 d。恩替卡韦组与拉米夫定组的平均转阴时间、累积转阴率、再感染率,累积再感染率均无统计学差异。结论:在HBV低复制的情况下,恩替卡韦、拉米夫定对术后HBV再感染的疗效相当,拉米夫定更经济。
[Abstract]:Objective: to compare the efficacy and economics of entecavir and lamivudine in preventing the recurrence of hepatitis B after liver transplantation in patients with low replication of HBV before operation. To explore the treatment strategy of preventing HBV reinfection after liver transplantation. Methods: a prospective study was conducted among the patients who underwent liver transplantation from July 2006 to July 2013 in our hospital. Results: 51 cases of entecavir group, the cumulative negative conversion rate of 1 month after operation was 98.04, and 3 cases of reinfection were found. The reinfection rate was 5.88 and the average time of negative conversion was 9.73 days. In lamivudine group, the cumulative negative conversion rate was 100 months after operation, 3 cases had HBV reinfection, the reinfection rate was 11.54 and the average negative conversion time was 5.11 d. The mean negative conversion time between entecavir group and lamivudine group was 5.11 d. Conclusion: under the condition of low replication of HBV, the efficacy of entecavir and lamivudine in the treatment of postoperative HBV reinfection is similar, and lamivudine is more economical.
【作者单位】：中山大学附属第三医院综合ICU;中山大学附属第一医院外科ICU;
【基金】：广东省自然科学基金(编号:S2013010015836;S2012010009104)
【分类号】：R657.3;R512.62

【参考文献】